Table 1 Patient/Treatment Characteristics
Variable | ACRT | STRT1 | STRT2 | Total | p-value | |
|---|---|---|---|---|---|---|
(45 Gy) | (60-63 Gy) | (> 63 Gy) | ||||
n = 119 | n = 90 | n = 91 | ||||
Age | median(range) | 68(41,100) | 67(44,88) | 73(47,95) | 69.5(41,100) | < 0.001 |
Gender | Female | 48(40.3%) | 43(47.8%) | 50(54.9%) | 141(47.0%) | 0.108 |
Male | 71(59.7%) | 47(52.2%) | 41(45.1%) | 159(53.0%) | ||
Smoking Status | Never | 8(6.8%) | 2(2.2%) | 4(4.4%) | 14(4.7%) | 0.224 |
Quit | 70(59.8%) | 45(50.6%) | 53(58.2%) | 168(56.6%) | ||
Current | 39(33.3%) | 42(47.2%) | 34(37.4%) | 115(38.7%) | ||
Karnofsky Performance Status score | 90 | 3(2.5%) | 5(5.6%) | 6(6.6%) | 14(4.7%) | < 0.001 |
80 | 35(29.4%) | 58(64.4%) | 40(44.0%) | 133(44.3%) | ||
70 | 47(39.5%) | 23(25.6%) | 38(41.8%) | 108(36.0%) | ||
≤ 60 | 34(28.6%) | 4(4.4%) | 7(7.7%) | 45(15.0%) | ||
Presenting Weight | No | 56(51.4%) | 67(75.3%) | 61(67.8%) | 184(63.9%) | 0.002 |
loss ≥ 5% | Yes | 53(48.6%) | 22(24.7%) | 29(32.2%) | 104(36.1%) | |
Tumor Stage | IIIA | 37(31.1%) | 50(55.6%) | 57(62.6%) | 144(48.0%) | < 0.001 |
IIIB | 82(68.9%) | 40(44.4%) | 34(37.4%) | 156(52.0%) | ||
Tumor Histology | Adenocarcinoma | 37(31.4%) | 31(35.2%) | 41(45.6%) | 109(36.8%) | 0.142 |
Squamous | 42(35.6%) | 34(38.6%) | 32(35.6%) | 108(36.5%) | ||
NSC-NOS | 39(33.1%) | 23(26.1%) | 17(18.9%) | 79(26.6%) | ||
Tumor Grade | Well | 3(2.5%) | 0(0%) | 4(4.4%) | 7(2.3%) | 0.069 |
Moderate | 11(9.2%) | 12(13.3%) | 10(11.0%) | 33(11.0%) | ||
Poor | 37(31.1%) | 42(46.7%) | 29(31.9%) | 108(36.0%) | ||
Unclear | 68(57.1%) | 36(40.0%) | 48(52.7%) | 152(50.7%) | ||
Tumor Size (cm) | median(range) | 5(1,11.5) | 5(1.5,10.5) | 4.2(1,9) | 5(1,11.5) | 0.039 |
Induction | No | 96(80.7%) | 29(32.2%) | 64(70.3%) | 189(63.0%) | < 0.001 |
Chemotherapy | Yes | 23(19.3%) | 61(67.8%) | 27(29.7%) | 111(37.0%) | |
Adjuvant | No | 105(88.2%) | 85(94.4%) | 86(94.5%) | 276(92.0%) | 0.15 |
Chemotherapy | Yes | 14(11.8%) | 5(5.6%) | 5(5.5%) | 24(8.0%) |